Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT (Cobenfy) switch study in schizophrenia
NCT05643170Phase 3Terminated
- Sponsor
- Karuna Therapeutics
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoints: The Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation, Investigator Assessment Questionnaire at Day 85 and 1 more. Started Nov 2022; status: terminated.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05643170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643170.